HB217 would require Kentucky Medicaid and any managed care organizations that contract with the Department for Medicaid Services to cover and reimburse rapid whole genome sequencing for certain children. The bill defines rapid whole genome sequencing as a test that analyzes the entire human genome, including mitochondrial DNA, and requires preliminary positive results within seven days and final results within fifteen days of sample receipt. Coverage would apply only to Medicaid beneficiaries under age 21 who are hospitalized in an intensive care unit or other high-acuity setting and who have a complex or acute illness of unknown cause, subject to detailed medical-necessity criteria.
The bill also sets out privacy and consent rules for genetic data generated through the covered testing. It treats the data as protected health information under HIPAA and HITECH, allows use in scientific research only with express informed consent, and permits patients or guardians to revoke that consent and require cessation of use and expungement from repositories. In addition, the Department for Medicaid Services would be required to adopt regulations to implement the new coverage and could expand coverage further for other next-generation sequencing and genetic testing.
Beyond Medicaid, HB217 amends Kentucky’s KCHIP statute to make KCHIP comply with the new rapid whole genome sequencing requirement. The KCHIP provisions in the bill largely restate existing program structure, including eligibility, benefits, premium caps, no copayments, provider contracting rules, and direct access to dental and vision care, while adding the new sequencing coverage as a required benefit. The bill also directs state agencies to seek any needed federal approvals, waivers, or state plan amendments within 90 days if required for implementation, and to report those requests to legislative committees.
The bill’s impact on state law would be to create a new mandatory Medicaid and KCHIP coverage category for rapid whole genome sequencing in narrowly defined pediatric cases, while also establishing state-level rules for handling the resulting genetic data. It would likely affect Medicaid beneficiaries, children enrolled in KCHIP, hospitals, laboratories, managed care organizations, and treating providers, and could require administrative rulemaking and possible federal approval before full implementation.
There is no recorded committee transcript or vote history provided, so the general sentiment cannot be measured from debate or roll calls. Based on the bill text alone, the measure appears policy-driven and supportive of expanded access to advanced diagnostic testing for critically ill children, while also attempting to address privacy concerns. Potential contention would likely center on cost, Medicaid and KCHIP coverage mandates, the need for federal approval, the scope of medical-necessity criteria, and how genetic data may be used or expunged after consent is revoked.
HB217 would amend Kentucky Medicaid law and KCHIP to require coverage of rapid whole genome sequencing for eligible pediatric patients in high-acuity hospital settings, subject to detailed medical-necessity standards. It would also create new statutory protections and consent rules for genetic data, require administrative regulations for implementation, and direct state agencies to seek any necessary federal approvals or waivers before full implementation. The bill would affect the Department for Medicaid Services, the Cabinet for Health and Family Services, managed care organizations, hospitals, laboratories, and families of covered children.
No committee discussion or vote record was provided, so there is no documented legislative sentiment to summarize from debate or voting. On its face, the bill is framed as a health coverage and diagnostic access measure for critically ill children, with privacy safeguards for genetic data, suggesting a generally supportive policy rationale. Any opposition would likely come from concerns about fiscal impact, administrative complexity, and federal approval requirements rather than from the underlying medical purpose.
The main likely points of contention are the cost of mandating coverage for rapid whole genome sequencing under Medicaid and KCHIP, whether the medical-necessity criteria are too broad or too narrow, and whether the state can implement the mandate without losing federal funds or needing federal approval. Another possible area of debate is the bill’s treatment of genetic data, including research use with consent and the requirement to expunge data after revocation, which may raise operational and privacy questions for providers and data repositories. No specific objections or supporters are identified in the provided materials.